A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Hospital Universitario Austral
-
-
-
-
-
Porto Alegre, Brazil
- Hospital de Clínicas de Porto Alegre
-
São Paulo, Brazil
- Instituto de Genética e Erros Inatos do Metabolismo
-
-
-
-
-
Bogotá, Colombia
- Fundación Cardio Infantil - Instituto de Cardiología
-
-
-
-
-
Lyon, France
- Hôpital Femme Mère Enfant
-
Montpellier, France
- Chu De Montpellier Hopital Gui De Chauliac
-
Paris, France
- Hôpital Armand Trousseau
-
-
-
-
-
Giessen, Germany
- Universitätsklinikum Giessen
-
Hamburg, Germany
- Universitätsklinikum Hamburg-Eppendorf
-
Höchheim, Germany
- SphinCS GmbH
-
Mainz, Germany
- Universitätsmedizin Mainz
-
-
-
-
-
Afula, Israel, 1834111
- Clalit Health Services Ha'Emek Medical Center
-
Ramat Gan, Israel, 6265601
- Sheba Medical Center
-
-
-
-
-
Rome, Italy
- Osp. Pediatrico Bambino Gesù, IRCCS
-
-
-
-
-
Krakow, Poland
- Uniwersytecki Szpital Dziecięcy
-
-
-
-
-
Barcelona, Spain
- Hospital Sant Joan de Déu
-
-
-
-
-
Ankara, Turkey (Türkiye)
- Gazi University Medicine Faculty Hospital
-
Izmir, Turkey (Türkiye)
- Ege University Children Hospital
-
-
-
-
-
London, United Kingdom
- Great Ormond Street Hospital for Children NHS Trust - Metabolic Medicine
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Hospital
-
-
California
-
Oakland, California, United States, 94609
- UCSF Benioff Children's Hospital Oakland
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Irving Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina at Chapel Hill Medical School Wing E
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A patient who voluntarily signs an Institutional Review Board or Independent Ethics Committee-approved written informed consent form. If the patient is aged under 18 years (aged under 16 years in the UK) at the time of enrollment or willingness to participate in the study cannot be confirmed due to MPS II-related intellectual disability, the patient's legally acceptable representative (e.g., his/her parents or guardians) may sign the informed consent on behalf of the patient. Written informed assent should be obtained from the patient, wherever possible.
- Patients with confirmed diagnosis of MPS II
- Naïve patients or patients who are receiving stable enzyme replacement therapy with idursulfase for more than 12 weeks before starting administration of JR-141 or idursulfase for this study.
- Patients or patients whose partners are of child-bearing potential agree to use a medically accepted, highly effective method of contraception being use of condoms from the time of informed consent.
<Cohort A>
- Patients aged 36-42 months old at the time of ICF signing: patients must have a standard score measured by the BSID-III of 85 or less at screening.
- Patients aged 43-71 months old at the time of ICF signing: patients must EITHER have (1) A DQ measured by BSID-III of 20 to 85 at screening OR (2) A composite standard score on NVI measured by KABC-II of 85 or less at screening (only who can perform KABC-II)
- Patients aged 30-35 months old at the time of randomization and who are judged as having the severe phenotype by the Expert Board.
<Cohort B>
- Patients 6 years of age or older at the time of ICF signing and whose IQ are 70 and higher.
- Enrollment of subjects in Cohort B is contingent on the availability in that country of a validated country-specific version of the test (either WISC-V, WAIS-IV, or T.O.V.A.).
- Attenuated patients with 1 SD deficiency in the omission errors or variability domains of the T.O.V.A..
- Patients or patients whose female partners are of child-bearing potential i.e., fertile, following menarche and until becoming post-menopausal unless permanently sterile, agree to use a medically accepted, highly effective method of contraception, from the time of informed consent. The method of contraception must be used during the study until 90 days for male subjects, and 30 days for female subjects after the final study intervention administration.
- For subjects with hearing impairment requiring hearing aid(s), every effort has been made to encourage compliance with the use of functioning hearing aid(s) before baseline neurocognitive assessments, and parent/legally acceptable representative or subject agrees to encourage wearing them during the study and on neurocognitive testing days.
Exclusion Criteria:
- A patient with a history of HSCT with successful engraftment.
- A patient who has received gene therapy treatment at any point.
- A patient who is judged by the principal investigator or sub-investigator as being unable to undergo lumbar puncture, including those who have difficulties in taking position for lumbar puncture due to joint contracture or those who are likely to experience breathing difficulties during the lumbar puncture process.
- A patient who is enrolled in another clinical study that involves clinical investigations or use of any investigational product (drug or device) within 4 months before obtaining informed consent.
- Unable to comply with the protocol as determined by the principal investigator or subinvestigator.
- Judged by the principal investigator or subinvestigator to be ineligible to participate in the study due to a history of serious drug allergy or sensitivity including anesthesia or hypersensitivity to any component of JR-141.
- A patient who has a known or suspected local or general infection or is at risk of abnormal bleeding due to medical conditions or therapies.
- A patient who has documented mutation of other genes, including loci adjacent to the IDS gene that are known to be associated with developmental delay, seizures, or other significant CNS disorders.
- A patient who has documented loss of activity of sulfatases other than IDS.
- A patient who has had a ventriculoperitoneal shunt placed or any other brain surgery, or has a clinically significant ventriculoperitoneal shunt malfunction within 30 days of screening.
- A patient who is full time employee of the sponsor or research site personnel directly affiliated with this study or their immediate family members.
- A patient who otherwise is judged by the principle investigator or sub-investigator to be ineligible to participate in the study.
- The subject has a positive pregnancy test or is breastfeeding at screening or randomization.
[Only in France]
- Persons deprived of their liberty by a judicial or administrative decision, according to article L.1121-6 the Public Health Code (Code de la santé publique), adults who are the subject of a measure of legal protection or unable to express their consent according to article L. 1121-8 of the Code de la santé publique)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: JR-141 2.0 mg/kg/week
|
IV infusion, 2.0 mg/kg/week |
|
Other: Rescue arm
|
The subjects who have achieved the pre-specified criteria* are able to change the drug. *If a subject in Idursulfase group shows decline in their neurocognitive outcome, idursulfase can be switched to JR-141. If a subject in JR-141 group shows decline in their peripheral outcome, JR-141 will be switched to idursulfase. |
|
Other: administered as the standard of care: idursulfase (ELAPRASE®)
standard of care-controlled study |
IV infusion |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in levels of cerebrospinal fluid heparan sulfate from baseline (Cohort A)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
|
Change in the raw scores of cognitive testing measured from baseline (BSID-III) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
For regions other than US: Change in the age equivalent scores of cognitive testing measured from baseline (BSID-III or KABC-II) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
|
For regions other than US: Change in the age equivalent scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
|
For the US: Change in the raw scores of adaptive behavior measured from baseline (VABS-II) (Cohort A)
Time Frame: Baseline to Week 105
|
Baseline to Week 105
|
|
For all regions: Relative change in liver volume relative to body weight from baseline (Cohort A and Cohort B)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
|
For all regions: Relative change in spleen volume relative to body weight from baseline (Cohort A and Cohort B)
Time Frame: Baseline to Week 53
|
Baseline to Week 53
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Metabolism, Inborn Errors
- Genetic Diseases, Inborn
- Metabolic Diseases
- Connective Tissue Diseases
- Neurobehavioral Manifestations
- Heredodegenerative Disorders, Nervous System
- Intellectual Disability
- Genetic Diseases, X-Linked
- Carbohydrate Metabolism, Inborn Errors
- Lysosomal Storage Diseases
- Mucinoses
- Mucopolysaccharidoses
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- X-Linked Intellectual Disability
- Mucopolysaccharidosis II
- idursulfase
Other Study ID Numbers
Other Study ID Numbers
- JR-141-GS31
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.